0 avis
Inflammation is a potential risk factor of voriconazole overdose in hematological patients
Archive ouverte
International audience. Abstract Voriconazole ( VRC ) overdoses are frequent and expose patients at high risk of adverse effects. This case–control study performed in hematological patients who benefited from VRC therapeutic drug monitoring from January 2012 to December 2015 aimed to identify risk factors of VRC overdose. Pharmacogenetic, biological, and demographic parameters at the time of VRC trough concentration ( C min ) were retrospectively collected from medical records. Cases ( VRC overdose: defined by a VRC C min ≥ 4 mg/L; n = 31) were compared to controls (no VRC overdose: defined by VRC C min < 4 mg/L; n = 31) using nonparametric or chi‐square tests followed by multivariable analysis. VRC overdoses were significantly associated with high CRP and bilirubin levels, intravenous administration, and age in univariable analysis. In contrast, the proportion of CYP genotypes ( CYP 2C19, CYP 3A4, or CYP 3A5, considered alone or combined in a combined genetic score) were not significantly different between patients who experienced a VRC overdose and those who did not. In multivariable analysis, the class of CRP level (defined by median CRP levels of 96 mg/L) was the sole independent risk factor of VRC overdose ( P < 0.01). Patients with CRP levels > 96 mg/L) had a 27‐fold ( IC 95%: [6–106]) higher risk of VRC overdose than patients with CRP levels ≤ 96 mg/L. This study demonstrates that inflammatory status, assessed by CRP levels, is the main risk factor of VRC overdose in French hematological patients, whereas pharmacogenetic determinants do not appear to be involved.
Consulter en ligne
Suggestions
Du même auteur
